These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22616988)

  • 1. MF101: a multi-component botanical selective estrogen receptor beta modulator for the treatment of menopausal vasomotor symptoms.
    Leitman DC; Christians U
    Expert Opin Investig Drugs; 2012 Jul; 21(7):1031-42. PubMed ID: 22616988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MF-101, an estrogen receptor beta agonist for the treatment of vasomotor symptoms in peri- and postmenopausal women.
    Stovall DW; Pinkerton JV
    Curr Opin Investig Drugs; 2009 Apr; 10(4):365-71. PubMed ID: 19337958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial.
    Grady D; Sawaya GF; Johnson KC; Koltun W; Hess R; Vittinghoff E; Kristof M; Tagliaferri M; Cohen I; Ensrud KE
    Menopause; 2009; 16(3):458-65. PubMed ID: 19182698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective activation of estrogen receptor-beta transcriptional pathways by an herbal extract.
    Cvoro A; Paruthiyil S; Jones JO; Tzagarakis-Foster C; Clegg NJ; Tatomer D; Medina RT; Tagliaferri M; Schaufele F; Scanlan TS; Diamond MI; Cohen I; Leitman DC
    Endocrinology; 2007 Feb; 148(2):538-47. PubMed ID: 17095596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinically meaningful efficacy of a non-estrogen agent: re-analysis of phase-2 data evaluating MF101.
    Tagliaferri M; Creasman J; Caygill KA; Olyaie A; Leitman D; Cohen I; Grady D
    Climacteric; 2012 Dec; 15(6):607-10. PubMed ID: 22257013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging hormonal treatments for menopausal symptoms.
    Genazzani AR; Komm BS; Pickar JH
    Expert Opin Emerg Drugs; 2015 Mar; 20(1):31-46. PubMed ID: 25557757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex.
    Pickar JH; Mirkin S
    Menopause Int; 2010 Sep; 16(3):121-8. PubMed ID: 20956688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aprela, a single tablet formulation of bazedoxifene and conjugated equine estrogens (Premarin) for the potential treatment of menopausal symptoms.
    Stovall DW
    Curr Opin Investig Drugs; 2010 Apr; 11(4):464-71. PubMed ID: 20336595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist.
    Mersereau JE; Levy N; Staub RE; Baggett S; Zogovic T; Chow S; Ricke WA; Tagliaferri M; Cohen I; Bjeldanes LF; Leitman DC
    Mol Cell Endocrinol; 2008 Feb; 283(1-2):49-57. PubMed ID: 18177995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective herbal treatment of vasomotor symptoms--are we any closer?
    Kaunitz AM
    Menopause; 2009; 16(3):428-9. PubMed ID: 19169160
    [No Abstract]   [Full Text] [Related]  

  • 11. Isoflavones and women's health.
    Powles T
    Breast Cancer Res; 2004; 6(3):140-2. PubMed ID: 15084236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy.
    Rossouw JE; Manson JE; Kaunitz AM; Anderson GL
    Obstet Gynecol; 2013 Jan; 121(1):172-6. PubMed ID: 23262943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention.
    Pinkerton JV; Pickar JH; Racketa J; Mirkin S
    Climacteric; 2012 Oct; 15(5):411-8. PubMed ID: 22853444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of menopausal vasomotor symptoms.
    Med Lett Drugs Ther; 2004 Dec 6-20; 47(1197-1198):98-9. PubMed ID: 15583526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bazedoxifene when paired with conjugated estrogens is a new paradigm for treatment of postmenopausal women.
    Pinkerton JV; Stovall DW
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1613-21. PubMed ID: 21073353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue-selective estrogen complex bazedoxifene and conjugated estrogens for the treatment of menopausal vasomotor symptoms.
    Stovall DW; Tanner-Kurtz K; Pinkerton JV
    Drugs; 2011 Sep; 71(13):1649-57. PubMed ID: 21902289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue-selective Estrogen Complex for Menopausal Hormone Therapy.
    Pinkerton JV
    Clin Obstet Gynecol; 2018 Sep; 61(3):463-469. PubMed ID: 29851863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Undertreatment of menopausal symptoms and novel options for comprehensive management.
    Lewis V
    Curr Med Res Opin; 2009 Nov; 25(11):2689-98. PubMed ID: 19775194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in menopausal therapy: the tissue-selective estrogen complex.
    Moore A
    J Am Assoc Nurse Pract; 2013 Mar; 25(3):126-33. PubMed ID: 24218199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety.
    Stovall DW; Utian WH; Gass ML; Qu Y; Muram D; Wong M; Plouffe L
    Menopause; 2007; 14(3 Pt 1):510-7. PubMed ID: 17314736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.